BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,050 filers reported holding BAXTER INTL INC in Q4 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,739,006 | -12.2% | 73,357 | -7.2% | 0.36% | -29.4% |
| Q3 2022 | $4,257,000 | -3.5% | 79,054 | +15.0% | 0.51% | +2.2% |
| Q2 2022 | $4,413,000 | -24.0% | 68,715 | -8.2% | 0.50% | -13.1% |
| Q1 2022 | $5,803,000 | +121.5% | 74,841 | +145.2% | 0.58% | +137.9% |
| Q4 2021 | $2,620,000 | -3.5% | 30,523 | -9.6% | 0.24% | -7.3% |
| Q3 2021 | $2,714,000 | +11.8% | 33,755 | +11.9% | 0.26% | +15.9% |
| Q2 2021 | $2,427,000 | -4.1% | 30,156 | +0.4% | 0.23% | -11.0% |
| Q1 2021 | $2,531,000 | +43.8% | 30,021 | +36.8% | 0.25% | +39.6% |
| Q4 2020 | $1,760,000 | -6.6% | 21,939 | -6.4% | 0.18% | -11.2% |
| Q3 2020 | $1,885,000 | +21.4% | 23,438 | +29.9% | 0.20% | +16.5% |
| Q2 2020 | $1,553,000 | -51.3% | 18,037 | +67.1% | 0.18% | -60.1% |
| Q1 2020 | $3,186,000 | +301.3% | 10,795 | +13.7% | 0.44% | +431.3% |
| Q4 2019 | $794,000 | -4.3% | 9,492 | 0.0% | 0.08% | -3.5% |
| Q3 2019 | $830,000 | +6.8% | 9,492 | 0.0% | 0.09% | +6.2% |
| Q2 2019 | $777,000 | -17.4% | 9,492 | -18.0% | 0.08% | -10.0% |
| Q1 2019 | $941,000 | -9.3% | 11,569 | -26.7% | 0.09% | -37.1% |
| Q4 2018 | $1,038,000 | – | 15,777 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |